<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2203">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 19, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01568255</url>
  </required_header>
  <id_info>
    <org_study_id>23187</org_study_id>
    <nct_id>NCT01568255</nct_id>
  </id_info>
  <brief_title>Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms</brief_title>
  <official_title>Is Treatment of Vitamin D Deficiency Associated With Resolution of Statin-Induced Muscular Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cedars-Sinai Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Statins are a class of drugs that are highly effective at lowering cholesterol levels.&#xD;
      However, compliance is often limited by symptoms of muscle pain. The investigators would like&#xD;
      to study Vitamin-D deficient individuals who also have muscle pain due to statin use. About 1&#xD;
      billion people are estimated to have low or insufficient levels of vitamin D worldwide.&#xD;
      Patients with low or insufficient levels of vitamin D may develop muscle disease. The purpose&#xD;
      of this study is to identify if these symptoms are associated with vitamin D deficiency, and&#xD;
      most importantly, if treatment of vitamin D deficiency can reduce muscle pain that is caused&#xD;
      by statin treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vitamin D2 (Ergocalciferol) is approved by the FDA to treat Vitamin D deficiency and will be&#xD;
      given according to approved labeling. This drug has not been systematically studied to test&#xD;
      the potential benefits of Vitamin D in patients who suffer from statin-induced muscle pain.&#xD;
      Vitamin D2 is the current standard of care for treating vitamin D deficiency. Since the&#xD;
      investigators are using Vitamin D2 therapy to treat vitamin D deficiency, and because our&#xD;
      trial is a pilot study, the data will not be submitted to the FDA for consideration of&#xD;
      changing the labeled indications for Vitamin D2 therapy.&#xD;
&#xD;
      This is a randomized, double-blinded, and placebo-controlled pilot study that will only be&#xD;
      performed at CSMC. 40 females with moderate to severe myopathic pain while on Simvastatin&#xD;
      will be enrolled in this study and will be randomized at a 1:1 ratio. Patients who will be&#xD;
      approached are considering an alternative statin medication as part of their clinical care to&#xD;
      address their muscle pain.&#xD;
&#xD;
      Participants will be recruited from the investigators' clinic patients. The study will be&#xD;
      discussed with a patient during clinical visit by the treating doctor. Interested individuals&#xD;
      will be provided with a copy of the consent form to take home for review with friends,&#xD;
      family, and other physicians. The patient may then call the study staff to set a study&#xD;
      appointment or enroll in the study during the clinical visit. A study investigator will&#xD;
      discuss the study with the patient and ask the patient to read through the consent. The&#xD;
      investigator will encourage the patient to ask any questions or discuss any concerns she&#xD;
      might have.&#xD;
&#xD;
      If the consenting investigator is also the patient's treating doctor, the consenting&#xD;
      investigator will request that the study coordinator approach the patient to determine the&#xD;
      patient's interest in the study in order to avoid a conflict of interest. The coordinator&#xD;
      will explicitly tell the patient that the patient's participation in the study is completely&#xD;
      voluntary and that the patient's medical care will not be affected should she choose not to&#xD;
      participate.&#xD;
&#xD;
      Participation in this study will be approximately 8 weeks. 20 participants will be randomized&#xD;
      to the treatment group and 20 to the placebo group. The treatment group will receive Vitamin&#xD;
      D2 therapy at 50,000 IU for 8 weeks (once per week) while the placebo group will receive a&#xD;
      placebo pill (once per week) that is identical in nature. Participants have 2 study visits&#xD;
      respectively at Week 0 and Week 8, and 1 phone follow-up visit at Week 1. In addition to the&#xD;
      administration of Vitamin D2 or placebo mentioned above, other study procedures include&#xD;
      informed consent, physical exam, questionnaires (brief pain assessment, and SF-12 to assess&#xD;
      limitations on physical activity), review of medical records, medication and supplement&#xD;
      review, blood draw, and phone followup. Subjects will be asked to stop any supplemental&#xD;
      Vitamin D therapy to maintain an equal dose within patients in the Vitamin D2 and placebo&#xD;
      group.&#xD;
&#xD;
      Prior to randomization, statin medication will be changed from Simvastatin to Atorvastatin&#xD;
      and patients will be followed up by telephone at Week 1 for tolerability of the new statin&#xD;
      medication. When a patient is intolerant to a particular statin, it is the standard of care&#xD;
      to attempt another statin medication. Typically, many choose atorvastatin since a lower dose&#xD;
      of the drug can be used to obtain the same target LDL/HDL, and lower doses reduce the risk of&#xD;
      toxicity. This change in medication would be preformed regardless of the research protocol.&#xD;
      Since the statin will be switched to a lower dose, it is possible that it will be a&#xD;
      confounding factor, however, even the placebo group will be switched to the same alternate&#xD;
      statin, reducing the differences between the two groups. In addition, Atorvastatin is also&#xD;
      metabolized by the CYP3A4 enzyme, and because the presumed mechanism of association between&#xD;
      vitamin D deficiency and statin-induced myopathic pain pivots on this enzyme, the&#xD;
      investigators wanted to choose a statin that continues to utilize this enzyme. But, for&#xD;
      reasons stated above, Atorvastatin has less myopathic symptoms due to lower doses used.&#xD;
&#xD;
      At the conclusion of the study, those in the treatment group whose serum 25 OH D levels have&#xD;
      reached &gt; 30ng/mL (therapeutic) may continue on maintenance doses on ergocalciferol (1,000&#xD;
      Units/day) if they are receiving clinical benefit. For those whose 25 OH D levels are &lt;&#xD;
      30ng/mL, regardless of whether they received clinical benefit or not from the treatment arm,&#xD;
      they will be offered a repeated 8 week course of Ergocalciferol therapy at 50,000 Units/week&#xD;
      under standard of care. It will be up to the patient to accept or decline the therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2012</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study was prospective, randomized, and double blinded pilot Ergocalciferol 50,000 IU once weekly for 8 weeks compared to Placebo in statin myalgic women. Subjects screened for eligibility underwent baseline and exit visits. For baseline and exit visits, subjects had safety labs drawn for lipid and vitamin D levels, completed Brief Pain Inventory (BPI) severity and interference questionnaires, as well as a Short Form (SF-12) questionnaire and medical history.Additionally, subjects underwent physical exams for baseline visits. After physical exams, subjects were then randomized to Placebo or Ergocalciferol treatment.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This is a randomized, double-blinded, and placebo-controlled pilot study of13 females with moderate to severe myopathic pain while on statins who were enrolled and randomized at a 1:1 ratio.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Reduction in Myopathic Pain</measure>
    <time_frame>8 weeks</time_frame>
    <description>To investigate if Vitamin D therapy reduces myopathic pain in subjects on statin medication who have low vitamin D levels and experience myopathic pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Pain Inventory (BPI) Severity at Exit</measure>
    <time_frame>8 weeks</time_frame>
    <description>Brief Pain Inventory (BPI) severity and interference questionnaires. BPI Severity Scale from 0 (Low Pain) to 10 (High Pain).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vitamin 25 OH D Levels</measure>
    <time_frame>8 weeks</time_frame>
    <description>Assessed with serum measurements</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brief Pain Inventory (BPI) Interference at Exit</measure>
    <time_frame>8 weeks</time_frame>
    <description>Brief Pain Inventory (BPI) severity and interference questionnaires. BPI Severity on a scale from 1 (Low Interference) to 10 (High Interference).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile - Total Cholesterol Levels</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile - LDL Cholesterol Levels</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile - HDL Cholesterol Levels</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid Profile - Triglycerides Levels</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Myopathic Symptoms</condition>
  <arm_group>
    <arm_group_label>Vitamin D Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin D Treatment Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo at 50,000IU for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ergocalciferol</intervention_name>
    <description>Ergocalciferol therapy at 50,000IU for 8 weeks</description>
    <arm_group_label>Vitamin D Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo at 50,000IU for 8 weeks</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female gender (refer to section 4)&#xD;
&#xD;
          2. Age &gt; 18, using an effective form of contraception (refer to section 4)&#xD;
&#xD;
          3. An indication to be on statin therapy&#xD;
&#xD;
          4. Moderate to severe myopathic pain while on Simvastatin&#xD;
&#xD;
          5. Serum CK level &lt; 10 x ULN&#xD;
&#xD;
          6. Vitamin 25 OH D level &lt; 30 ng/mL (as secondary hyperparathyroidism is triggered below&#xD;
             this level)1&#xD;
&#xD;
          7. English speaking patients only&#xD;
&#xD;
          8. Myopathic pain that cannot be attributed to other medical conditions&#xD;
&#xD;
          9. Continue a statin within the CYP3A4 family&#xD;
&#xD;
         10. Competent to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinical diagnosis of overt vitamin D deficiency: osteomalacia, rickets, hypocalcemia,&#xD;
             hypophosphatemia&#xD;
&#xD;
          2. Already taking Vitamin D supplements &gt; 1000 IU/day&#xD;
&#xD;
          3. Serum creatinine &gt; 2.2 mg/dL within last 6 months&#xD;
&#xD;
          4. AST/ALT &gt; 3 x ULN of the local reference range&#xD;
&#xD;
          5. Serum CK level &gt; 10 x ULN&#xD;
&#xD;
          6. Systolic blood pressure &lt; 100 mmHg&#xD;
&#xD;
          7. Albumin adjusted calcium &gt; 2.55 mmol/L or &lt; 2.20 mmol/L&#xD;
&#xD;
          8. Renal osteodystrophy&#xD;
&#xD;
          9. Malabsorption syndrome&#xD;
&#xD;
         10. Metastatic malignancy&#xD;
&#xD;
         11. Transplant recipients&#xD;
&#xD;
         12. A co-existent diagnosis of renal calculi within the previous 6 months&#xD;
&#xD;
         13. A co-existent diagnosis of primary hyperparathyroidism within the previous 6 months&#xD;
&#xD;
         14. Recent therapy with corticosteroids within the previous 6 months&#xD;
&#xD;
         15. Currently consuming Digoxin, as usage increases risk of hypercalcemia&#xD;
&#xD;
         16. Lactating women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Margo B. Minissian, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cedars-Sinai Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 29, 2012</study_first_submitted>
  <study_first_submitted_qc>March 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 2, 2012</study_first_posted>
  <results_first_submitted>December 22, 2020</results_first_submitted>
  <results_first_submitted_qc>May 17, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">June 10, 2021</results_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cedars-Sinai Medical Center</investigator_affiliation>
    <investigator_full_name>Margo B. Minissian</investigator_full_name>
    <investigator_title>Executive Director, Brawerman Nursing Institute</investigator_title>
  </responsible_party>
  <keyword>myopathic symptoms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data was presented by poster presentation internally at Cedars-Sinai Medical Center. The plan is to publish the manuscript.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>The data is currently available</ipd_time_frame>
    <ipd_access_criteria>We plan to submit manuscript for peer review.</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 4, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/55/NCT01568255/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Vitamin D Treatment</title>
          <description>Vitamin D Treatment Group&#xD;
Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group</title>
          <description>Placebo at 50,000IU for 8 weeks&#xD;
Placebo: placebo at 50,000IU for 8 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Vitamin D Treatment</title>
          <description>Vitamin D Treatment Group&#xD;
Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group</title>
          <description>Placebo at 50,000IU for 8 weeks&#xD;
Placebo: placebo at 50,000IU for 8 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="6"/>
                    <count group_id="B3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Diabetes</title>
          <population>5/6 placebo participants provided an answer to history of diabetes. 1/6 placebo participants did not provide an answer to history of diabetes</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of High Cholesterol</title>
          <population>5/6 placebo participants provided an answer to history of high cholesterol. 1/6 placebo participants did not provide an answer to history of high cholesterol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of High Blood Pressure</title>
          <population>5/6 placebo participants provided an answer to a history of high blood pressure. 1/6 participants did not provide an answer to a history of high blood pressure</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of High Triglyceride</title>
          <population>5/6 placebo participants provided an answer to history of high triglycerides. 1/6 placebo participants did not provide an answer to a history of high triglycerides</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="5"/>
                    <count group_id="B2" value="5"/>
                    <count group_id="B3" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Family History of Coronary Heart Disease</title>
          <population>4/5 Vitamin D participants provided an answer to family history of coronary heart disease. 4/5 Vitamin D participants did not provide an answer to family history of coronary heart disease. 4/6 placebo participants provided an answer to family history of coronary heart disease. 2/6 placebo participants did not provide an answer to family history of coronary heart disease.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="4"/>
                    <count group_id="B2" value="4"/>
                    <count group_id="B3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Reduction in Myopathic Pain</title>
        <description>To investigate if Vitamin D therapy reduces myopathic pain in subjects on statin medication who have low vitamin D levels and experience myopathic pain.</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Treatment</title>
            <description>Vitamin D Treatment Group&#xD;
Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo at 50,000IU for 8 weeks&#xD;
Placebo: placebo at 50,000IU for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Reduction in Myopathic Pain</title>
          <description>To investigate if Vitamin D therapy reduces myopathic pain in subjects on statin medication who have low vitamin D levels and experience myopathic pain.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Brief Pain Inventory (BPI) Severity at Exit</title>
        <description>Brief Pain Inventory (BPI) severity and interference questionnaires. BPI Severity Scale from 0 (Low Pain) to 10 (High Pain).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Treatment</title>
            <description>Vitamin D Treatment Group&#xD;
Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo at 50,000IU for 8 weeks&#xD;
Placebo: placebo at 50,000IU for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory (BPI) Severity at Exit</title>
          <description>Brief Pain Inventory (BPI) severity and interference questionnaires. BPI Severity Scale from 0 (Low Pain) to 10 (High Pain).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.5625" spread="2.6877"/>
                    <measurement group_id="O2" value="3.8125" spread="2.4612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Vitamin 25 OH D Levels</title>
        <description>Assessed with serum measurements</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Treatment</title>
            <description>Vitamin D Treatment Group&#xD;
Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo at 50,000IU for 8 weeks&#xD;
Placebo: placebo at 50,000IU for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Vitamin 25 OH D Levels</title>
          <description>Assessed with serum measurements</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.075" spread="4.537"/>
                    <measurement group_id="O2" value="18.05" spread="6.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Profile - Total Cholesterol Levels</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Treatment</title>
            <description>Vitamin D Treatment Group&#xD;
Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo at 50,000IU for 8 weeks&#xD;
Placebo: placebo at 50,000IU for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Profile - Total Cholesterol Levels</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165.8" spread="37.89"/>
                    <measurement group_id="O2" value="197.67" spread="65.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Brief Pain Inventory (BPI) Interference at Exit</title>
        <description>Brief Pain Inventory (BPI) severity and interference questionnaires. BPI Severity on a scale from 1 (Low Interference) to 10 (High Interference).</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Treatment</title>
            <description>Vitamin D Treatment Group&#xD;
Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo at 50,000IU for 8 weeks&#xD;
Placebo: placebo at 50,000IU for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory (BPI) Interference at Exit</title>
          <description>Brief Pain Inventory (BPI) severity and interference questionnaires. BPI Severity on a scale from 1 (Low Interference) to 10 (High Interference).</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.85714285725" spread="1.97948663699"/>
                    <measurement group_id="O2" value="0.80952380967" spread="1.28041234868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Profile - LDL Cholesterol Levels</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Treatment</title>
            <description>Vitamin D Treatment Group&#xD;
Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo at 50,000IU for 8 weeks&#xD;
Placebo: placebo at 50,000IU for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Profile - LDL Cholesterol Levels</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.4" spread="28.64"/>
                    <measurement group_id="O2" value="106.83" spread="55.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Profile - HDL Cholesterol Levels</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Treatment</title>
            <description>Vitamin D Treatment Group&#xD;
Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo at 50,000IU for 8 weeks&#xD;
Placebo: placebo at 50,000IU for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Profile - HDL Cholesterol Levels</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" spread="5.72"/>
                    <measurement group_id="O2" value="63.5" spread="18.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lipid Profile - Triglycerides Levels</title>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Vitamin D Treatment</title>
            <description>Vitamin D Treatment Group&#xD;
Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group</title>
            <description>Placebo at 50,000IU for 8 weeks&#xD;
Placebo: placebo at 50,000IU for 8 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Lipid Profile - Triglycerides Levels</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="107.54" spread="0.8943"/>
                    <measurement group_id="O2" value="86.92" spread="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Vitamin D Treatment Group</title>
          <description>Vitamin D Treatment Group&#xD;
Ergocalciferol: Ergocalciferol therapy at 50,000IU for 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group</title>
          <description>Placebo at 50,000IU for 8 weeks&#xD;
Placebo: placebo at 50,000IU for 8 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Margo Minissian, PhD</name_or_title>
      <organization>Cedars Sinai</organization>
      <phone>310-423-5195</phone>
      <email>Margo.Minissian@cshs.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

